Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry

Get report
Skip to content

Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry

Get report
  • There are no suggestions because the search field is empty.
Request a Demo
Request a Demo

Core Capabilities

Featured

Radar metrics
BLOG The market has changed: Frost & Sullivan's 2026 Radar shows who's leading it RapidAI Chief Business Officer David Stoffel, MD, MBA, breaks down what this recognition signals — and what it means for health systems planning their AI strategy for the years ahead LEARN MORE
Platform overview
Request a Demo

RADIOLOGY SUPPORT

Neurovascular

Cardiac + vascular

LIFE SCIENCES

Featured

Cognitive Burden index RapidAI 2025
BLOG Radiology’s real challenge Read about the reality of cognitive burden LEARN MORE
Request a Demo

BUILT TO SUPPORT THE FULL SYSTEM

FEATURED

Resource_1600x900_C-Suite-Exec Insights_white paper
WHITE PAPER Empowering healthcare leaders with a deep clinical AI enterprise platform Learn how AI can address real-world challenges for administrators LEARN MORE
Overview
Request a Demo

Core Capabilities

Featured

Radiology Rewired podcast
PODCAST Season 1 available now Exploring how AI is transforming Radiology—one conversation at a time with clinicians and innovators LEARN MORE
Overview
Request a Demo

TRAINING & LEARNING

HELP & ASSISTANCE

Overview
Request a Demo

LEARN MORE ABOUT RAPIDAI

WORK WITH US

FEATURED

video thumbnail for dr Gregory Albers
VIDEO The story behind RapidAI Hear our founder, Greg Albers, MD, tell the history of how the company came to be Watch now
Company overview
Request a Demo
Press Release

iSchemaView Technology RAPIDly Adopted by Over 350 Stroke Centers

RAPID Becoming a New Standard in Advanced Cerebrovascular Imaging

Share to

RAPID Becoming a New Standard in Advanced Cerebrovascular Imaging

Redwood City, Calif. – April 24, 2018 – iSchemaView, the leader in cerebrovascular imaging analysis, today announced accelerating adoption of its platform. As of today over 350 stroke centers are now using RAPID advanced imaging technology to assist physicians in the analysis of brain images using automated tools for CT, CT Perfusion, MR diffusion and perfusion. With over 350 stroke centers now using RAPID around the world, regular daily use at the centers is generating over 50,000 scans a year. With 200 or more systems expected to come online in 2018, scan count is projected to approach 100,000 per year. “It is terrific to see the industry respond so dramatically to recent studies and adopt RAPID so quickly,” said Don Listwin, CEO of iSchemaView. “The most important result is that we are getting our complete imaging solution into as many hospitals as possible for the benefit of substantially more addressable patients. We want to put an end to time constrained ‘wait and see’ stroke outcomes, and put RAPID to work for all.” Under IRB approval, iSchemaView’s RAPID platform was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies helped change the AHA stroke guidelines to include CT Perfusion and MR perfusion. The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well. "Now there's the potential to treat based on best evidence not just best guess, that’s what RAPID’s perfusion platform affords,” said Christian Ramsey, MD, Neurosurgeon and Surgical Director of Stroke at Baptist Health System. “More patients with more treatment options offers the potential for successful outcomes in patients with historically terrible prognoses.” Today, Gregory W. Albers MD, Stanford University Neurologist and cofounder of iSchemaView, will also be presenting Expanding the Time Window for Thrombectomy: Results of the DEFUSE 3 Study at the Annual Meeting of The American Academy of Neurology in Los Angeles.

Contact PR

Jessica Stebing

Jessica Stebing

Group Manager, Marketing Communications

stebing@rapidai.com